TEVA in the 13F filings
Teva Pharmaceutical Inds LTD · CUSIP 881624209
- Quarter end
- 30 Jun 2024
- the date the book describes
- Filed
- 5 Nov 2026
- latest of these filings; the earliest 26 Jul 2024
- Managers listing it
- 22
- at least, of 95 tracked, among listed positions
- Comparable managers
- 94
- filed both Q1 2024 and Q2 2024; 16 listed it in both
- Shares listed
- 108,653,303
- combined, among listed positions
- Reported value
- $1.8bn
- combined, at the quarter end
Among the 94 comparable managers: 13 buyers (opened or added shares) and 7 sellers (trimmed or exited), at least, among listed positions. Their net change in shares is not known from listed positions, because at least one of them lists it in only one of the two quarters.
Managers listing TEVA in Q2 2024
22 of 22 holders
Largest increases and reductions, by shares
Increases
- Glenview Capital Management LLCexisting position · 9,157,641 shares now+1,656,357
- Millennium Management LLCexisting position · 12,128,177 shares now+1,379,392
- Davidson Kempner Capital Management LPexisting position · 1,765,485 shares now+1,066,150
- Renaissance Technologies LLCexisting position · 8,728,563 shares now+1,031,400
- Balyasny Asset Management LLCexisting position · 3,742,969 shares now+620,971
Reductions
- Holocene Advisors LPexisting position · 4,586,272 shares now-376,184
- Neuberger Berman Group LLCexisting position · 3,889,989 shares now-139,727
- Tudor Investment Corpexisting position · 855,001 shares now-90,048
- Two Sigma Advisers LPexisting position · 897,500 shares now-50,000
- Marshall Wace LLPexisting position · 4,172,593 shares now-42,623
New positions and exits
New (1)
Exited (0)
No exit shown by a manager’s own filing.
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q2 2013 | 14 | $5.5bn | n.a. | n.a. |
| Q3 2013 | 16 | $5.9bn | n.a. | n.a. |
| Q4 2013 | 17 | $5.4bn | n.a. | n.a. |
| Q1 2014 | 24 | $7.7bn | n.a. | n.a. |
| Q2 2014 | 24 | $7.3bn | n.a. | n.a. |
| Q3 2014 | 25 | $7.4bn | n.a. | n.a. |
| Q4 2014 | 25 | $8.1bn | n.a. | n.a. |
| Q1 2015 | 25 | $8.7bn | n.a. | n.a. |
| Q2 2015 | 26 | $8.2bn | n.a. | n.a. |
| Q3 2015 | 23 | $8.4bn | n.a. | n.a. |
| Q4 2015 | 25 | $12.8bn | n.a. | n.a. |
| Q1 2016 | 27 | $10.3bn | n.a. | n.a. |
| Q2 2016 | 22 | $8.8bn | n.a. | n.a. |
| Q3 2016 | 25 | $7.9bn | n.a. | n.a. |
| Q4 2016 | 19 | $6.6bn | n.a. | n.a. |
| Q1 2017 | 22 | $5.9bn | n.a. | n.a. |
| Q2 2017 | 14 | $6.2bn | n.a. | n.a. |
| Q3 2017 | 15 | $3.0bn | n.a. | n.a. |
| Q4 2017 | 14 | $4.1bn | n.a. | n.a. |
| Q1 2018 | 13 | $4.8bn | n.a. | n.a. |
| Q2 2018 | 18 | $7.0bn | n.a. | n.a. |
| Q3 2018 | 18 | $6.3bn | n.a. | n.a. |
| Q4 2018 | 19 | $4.9bn | n.a. | n.a. |
| Q1 2019 | 14 | $4.7bn | n.a. | n.a. |
| Q2 2019 | 14 | $2.8bn | n.a. | n.a. |
| Q3 2019 | 11 | $2.0bn | n.a. | n.a. |
| Q4 2019 | 9 | $2.9bn | n.a. | n.a. |
| Q1 2020 | 14 | $2.0bn | n.a. | n.a. |
| Q2 2020 | 12 | $2.8bn | n.a. | n.a. |
| Q3 2020 | 7 | $2.1bn | n.a. | n.a. |
| Q4 2020 | 5 | $2.2bn | n.a. | n.a. |
| Q1 2021 | 8 | $2.6bn | n.a. | n.a. |
| Q2 2021 | 7 | $2.1bn | n.a. | n.a. |
| Q3 2021 | 6 | $1.7bn | n.a. | n.a. |
| Q4 2021 | 4 | $1.1bn | n.a. | n.a. |
| Q1 2022 | 9 | $1.4bn | n.a. | n.a. |
| Q2 2022 | 11 | $913m | n.a. | n.a. |
| Q3 2022 | 11 | $1.4bn | n.a. | n.a. |
| Q4 2022 | 11 | $1.7bn | n.a. | n.a. |
| Q1 2023 | 8 | $1.3bn | n.a. | n.a. |
| Q2 2023 | 10 | $184m | n.a. | n.a. |
| Q3 2023 | 13 | $384m | n.a. | n.a. |
| Q4 2023 | 10 | $373m | 8 | 3 |
| Q1 2024 | 16 | $666m | 8 | 6 |
| Q2 2024 | 22 | $1.8bn | 13 | 7 |
| Q3 2024 | 22 | $2.3bn | 9 | 12 |
| Q4 2024 | 18 | $3.0bn | 8 | 11 |
| Q1 2025 | 12 | $2.0bn | 7 | 6 |
| Q2 2025 | 11 | $1.8bn | 6 | 5 |
| Q3 2025 | 14 | $964m | 9 | 4 |
| Q4 2025 | 16 | $2.1bn | 18 | 22 |
| Q1 2026 | 14 | $2.0bn | 20 | 19 |
| Q2 2026 | 14 | $2.4bn | 18 | 16 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
TEVA and LLY →TEVA and JNJ →TEVA and VRTX →Choose a stock to compare with TEVA →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own TEVA, latest filings →Back to the 13F Explorer →